Advertisement

Topics

Latest Urology NewsRSS

11:56 EDT 24th September 2017 | BioPortfolio

Maternal urinary fluoride/IQ study – an update

 The maternal urinary fluoride/IQ study  (Bashash et al., 2017) continues to get attention – but mainly from anti-fluoride organisations. The scientific community will evaluate the published report after giving it due consideration and there have already been criticisms. But anti-fluoride campaigners consider it the best thing since sliced bread. The Fluoride Action Network (FAN) describes [&#...

Mexico Nephrology and Urology Devices Market Outlook to 2023 Incontinence Devices, Lithotripters and Renal Dialysis Equipment [Report Updated: 07082017] Prices from USD $5995

Mexico Nephrology and Urology Devices Market Outlook to 2023 Incontinence Devices, Lithotripters and Renal Dialysis EquipmentSummaryGlobalData's new report, "Mexico Nephrology and Urology Market Outlook to 2023", provides key market data on the Mexico Nephrology and Urology market. The report provides value, in millions of US dollars and volume in units within market categories Incontinence Devi...

Global Urological Catheters Market 20172021 [Report Updated: 10082017] Prices from USD $3500

About Urological CathetersUrological catheters include the catheters involved for the management or the treatment of diseases related to the upper urinary tract such as urinary incontinence and urinary retention, blood management, and kidney stone management. Urological catheters mainly consist of dialysis catheters for vascular access, urinary catheters for urinary incontinence and retention, and...

Treat-and-extend comparable to monthly injections in AMD

A multicenter 12-month phase 3b study showed that treat-and-extend administration of ranibizumab is “statistically noninferior and clinically comparable” with monthly treatment in patients with neovascular age-related macular degeneration.The TREND study recruited 650 treatment-naïve patients with active choroidal neovascularization secondary to AMD in 90 centers across 18 countries, randomly...

Damage done to bodies after years of smoking could be reversed, ACS states

Primary Asset: Body:  Some of the body’s negative reactions to smoking—a risk factor for six of the world’s eight leading causes of death—could be reversible, new research from the American Chemical Society (ACS) states.Even after using tobacco for years, male test subjects displayed improved

GenomeDx Biosciences???s Decipher Cancer Classifier Tests And Genomic Database To Be Featured In Multiple Presentations At 2017

San Diego, California September 21, 2017 GenomeDx Biosciences, a leader in the field of urologic cancer genomics, today announced that it will present results from three studies featuring its Decipher Prostate and Bladder Cancer Classifier Tests and Decipher Genomics Resource Information Database (Decipher GRID) at the American Society for Radiation Oncology (ASTRO) Annual Meeting being held...

Eleven Bio Announces Completion Of Vicinium Manufacturing For Ongoing Clinical Trials In Non-Muscle Invasive Bladder Cancer

  Life Sciences Jobs   ...

GTX Corp To Host Key Opinion Leader Luncheon On The Topic Of Stress Urinary Incontinence On September 28th In New York City

  Life Sciences Jobs   ...

GTx to Host Key Opinion Leader Luncheon on the Topic of Stress Urinary Incontinence on September 28th in New York City

GTx, Inc. (Nasdaq: GTXI) today announced that it will be hosting and simultaneously webcasting a Key Opinion Leader (KOL) luncheon meeting on the topic of Stress Urinary Incontinence (SUI) on Thursday, September 28th in New York City beginning at 12:00 p.m. EDT. The meeting will feature presentations by key opinion leaders Roger Dmochowski, MD (Va...

The Law Offices of John David Hart: Texas Oncology Surgeon Performs Wrong Surgery on Cancer Patient

FORT WORTH, Texas, Sept. 21, 2017 /PRNewswire/ -- Bernice Marie Gomez filed suit against Sujeet Acharya, Texas Oncology, P.A. and Texas Urology Associates in the 160th District Court in and for Dallas County, Texas, Case Number DC-17-12969 on September 20, 2017.  The lawsuit alleges that a Texas Oncology surgeon, Sujeet Acharya, performed the wrong procedure on Ms. Gomez – removi...

FemTouch; a Revolution in Feminine Vaginal Health

Movie stars, health magazines and even talk shows are all a-buzz about vaginal rejuvenation procedures, which fix stress urinary incontinence, treat vaginal laxity, vaginal dryness, unbalanced pH and many more feminine issues. Derma Health, a top MedSpa in the U.S. is now offering this phenomenal treatment, called FemTouch™ by Lumenis. Phoenix, Arizona (PRWEB) September 21, 2017 Derma Health Sk...

Duchesnay Inc Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 27072017] Prices from USD $250

SummaryDuchesnay Inc Duchesnay is a pharmaceutical company that offers medications indicated for use in pregnancy. The company's products include Diclectin, an antinauseant drug used for the management of nausea and vomiting; PregVit, a supplement that allow attaining nutrient levels of folic acid, iron, and calcium; and ProctofoamHC, a mucoadhesive analgesic and antiinflammatory foam for the reli...

BCD Innovations Moves into New Laboratory Space at the FastForward 1812 Innovation Hub

September 21, 2017 (Baltimore, MD) – BCD Innovations, Inc. (“BCD”), a Baltimore-based healthcare diagnostic company that focuses on developing diagnostic innovations for cancer detection, announces that it has leased laboratory space at the FastForward 1812 innovation hub operated by Johns Hopkins Technology Ventures, the intellectual property administration center of Johns Hop...

Merck KGaA, Pfizer's cancer drug Bavencio gets EU nod

FRANKFURT: European regulators on Thursday granted market approval for Merck KGaA and Pfizer's immuno-oncology drug Bavencio to treat a rare and aggressive type of skin cancer called Merkel cell carcinoma. In May, Bavencio was approved by the U.S. Food and Drug Administration to treat bladder cancer and in March to treat Merkel cell carcinoma.

FDA Advisory Committee Recommends Approval of REMICADE® for Treatment of Pediatric Ulcerative Colitis

HORSHAM, Pa., July 21, 2011 /PRNewswire/ -- Janssen Biotech, Inc., formerly Centocor Ortho Biotech Inc., announced today that the Gastrointestinal Drugs Advisory Committee (GIDAC) of the U.S. Food and Drug Administration (FDA) recommended the approval of REMICADE® (infliximab) for the treatment of moderately to severely active ulcerative colitis (UC) in pediatric patients who have had an inad...

GenomeDx's Decipher Cancer Classifier Tests and Genomic Database to be Featured in Multiple Presentations at ASTRO 2017

SAN DIEGO, Sept. 21, 2017 /PRNewswire/ -- GenomeDx Biosciences, a leader in the field of urologic cancer genomics, today announced that it will present results from three studies featuring its Decipher® Prostate and Bladder Cancer Classifier Tests and Decipher Genomics Resource Information Database (Decipher GRID®) at the American Society for Radiation Oncology (ASTRO) Annual Meeting being held ...

Italy Incontinence Devices Market Outlook to 2023 [Report Updated: 07082017] Prices from USD $4995

Italy Incontinence Devices Market Outlook to 2023SummaryGlobalData's new report, "Italy Incontinence Devices Market Outlook to 2023", provides key market data on the Italy Incontinence Devices market. The report provides value, in millions of US dollars, volume in units and average prices USD within market segments Protective Garments for Incontinence, Urinary Catheters and Urine Bags.The report ...

Paratek Release: Omadacycline Receives Qualified Infectious Disease Product Designation From FDA For An Additional Indication In Uncomplicated Urinary Tract Infection

  Life Sciences Jobs   ...

Omadacycline Receives Qualified Infectious Disease Product Designation from FDA for an Additional Indication in Uncomplicated Urinary Tract Infections

Uncomplicated UTIs are among the most common bacterial infections with few oral treatment options BOSTON, Sept. 21, 2017 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon tetracycline chemistry, today announced that its investigational antibiotic omadacycline has bee...

Can Active Surveillance Be Expanded for Prostate Cancer Patients? (FREE)

Both low- and intermediate-risk patients did well, but follow-up averaged only 4 years.

Mexico Incontinence Devices Market Outlook to 2023 [Report Updated: 07082017] Prices from USD $4995

Mexico Incontinence Devices Market Outlook to 2023SummaryGlobalData's new report, "Mexico Incontinence Devices Market Outlook to 2023", provides key market data on the Mexico Incontinence Devices market. The report provides value, in millions of US dollars, volume in units and average prices USD within market segments Protective Garments for Incontinence, Urinary Catheters and Urine Bags.The repo...

OncLive® Presents State of the Science Summit™: Advanced Renal Cell and Bladder Cancer

This State of the Science Summit™ is taking place in partnership with Fox Chase Cancer Center OncLive®, a leading digital provider of resources and information for oncology professionals, announces the latest State of the Science Summit™: Advanced Renal Cell and Bladder Cancer, which will be held at 5:30 p.m. Wednesday, Sept. 27, 2017, at ...

Natera Selected for Circulating Tumor DNA Study in Bladder Cancer

SAN CARLOS, Calif., Sept. 20, 2017 /PRNewswire/ -- Natera, Inc., (NASDAQ: NTRA), a global leader in cell-free DNA testing, has entered into a research collaboration with Denmark's Aarhus University to leverage the company's Signatera™ (RUO) personalized liquid biopsy technology to evaluate circulating tumor DNA (ctDNA) as a useful biomarker in the diagnosis and treatment of bladder cancer. ...

Zavante Therapeutics To Present ZOLYD™ Data From Pivotal ZEUS Study At ID Week 2017

SAN DIEGO, Sept. 20, 2017 /PRNewswire/ -- Zavante Therapeutics, Inc., a biopharmaceutical company focused on developing novel therapies to improve the outcomes of hospitalized patients, and its research collaborators will present eight posters related to investigational antibiotic ZOLYD™ (fosfomycin for injection, also known as ZTI-01), at ID Week 2017 to be held October 4-8, 2017 in San Di...

South Korea Nephrology and Urology Devices Market Outlook to 2023 Incontinence Devices, Lithotripters and Renal Dialysis Equipment [Report Updated: 07082017] Prices from USD $5995

South Korea Nephrology and Urology Devices Market Outlook to 2023 Incontinence Devices, Lithotripters and Renal Dialysis EquipmentSummaryGlobalData's new report, "South Korea Nephrology and Urology Market Outlook to 2023", provides key market data on the South Korea Nephrology and Urology market. The report provides value, in millions of US dollars and volume in units within market categories In...

Quick Search
Advertisement
 

review and buy Urology market research data and corporate reports here